At the time of writing, Tarsus Pharmaceuticals Inc [TARS] stock is trading at $50.84, up 2.38%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The TARS shares have gain 9.15% over the last week, with a monthly amount glided 15.89%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Tarsus Pharmaceuticals Inc [NASDAQ: TARS] stock has seen the most recent analyst activity on November 20, 2023, when Goldman initiated its Neutral rating and assigned the stock a price target of $19. Previously, William Blair started tracking the stock with Outperform rating on July 18, 2023, and set its price target to $44. On May 18, 2023, Guggenheim initiated with a Buy rating. Barclays started tracking the stock assigning a Overweight rating and suggested a price target of $40 on August 01, 2022. H.C. Wainwright initiated its recommendation with a Buy and recommended $40 as its price target on December 21, 2021. Oppenheimer started tracking with a Outperform rating for this stock on November 23, 2021, and assigned it a price target of $55. In a note dated November 10, 2020, Raymond James initiated an Strong Buy rating and provided a target price of $39 on this stock.
For the past year, the stock price of Tarsus Pharmaceuticals Inc fluctuated between $15.60 and $52.99. Currently, Wall Street analysts expect the stock to reach $62 within the next 12 months. Tarsus Pharmaceuticals Inc [NASDAQ: TARS] shares were valued at $50.84 at the most recent close of the market. An investor can expect a potential return of 21.95% based on the average TARS price forecast.
Analyzing the TARS fundamentals
According to Tarsus Pharmaceuticals Inc [NASDAQ:TARS], the company’s sales were 129.62M for trailing twelve months, which represents an 2471.78% jump. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -1.08%, Pretax Profit Margin comes in at -1.04%, and Net Profit Margin reading is -1.04%. To continue investigating profitability, this company’s Return on Assets is posted at -0.36, Equity is -0.56 and Total Capital is -0.45. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.3.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 50.04 points at the first support level, and at 49.23 for the second support level. However, for the 1st resistance point, the stock is sitting at 51.55, and for the 2nd resistance point, it is at 52.26.
Ratios To Look Out For
It is important to note that Tarsus Pharmaceuticals Inc [NASDAQ:TARS] has a current ratio of 5.42. As well, the Quick Ratio is 5.38, while the Cash Ratio is 2.68. Considering the valuation of this stock, the price to sales ratio is 14.99, the price to book ratio is 8.18.
Transactions by insiders
Recent insider trading involved LINK WILLIAM J PHD, Director, that happened on Aug 12 ’24 when 35000.0 shares were sold. Director, FLYING L PARTNERS XI LLC completed a deal on Aug 12 ’24 to buy 35000.0 shares. Meanwhile, Farrow Jeffrey S sold 10445.0 shares on Jun 18 ’24.
